Notch1 phenotype and clinical stage progression in non-small cell lung cancer

Journal of Hematology and Oncology

Volumn 8, Issue 1, 2015, Pages

  Nguyen, Dat ^a   Rubinstein, Larry ^b   Takebe, Naoko ^b   Miele, Lucio ^c   Tomaszewski, Joseph E ^b   Ivy, Percy ^b   Doroshow, James H ^b   Yang, Sherry X ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Lung cancer; N1 ICD; Notch1; NSCLC; Stage

Indexed keywords

NOTCH1 RECEPTOR; NOTCH1 PROTEIN, HUMAN;

ARTICLE; CANCER STAGING; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INTRACELLULAR DOMAIN; LUNG CANCER CELL LINE; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; PHENOTYPE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE MICROARRAY; FEMALE; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; RECEPTOR, NOTCH1; TISSUE ARRAY ANALYSIS;

EID: 84924089217     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-014-0104-2     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013, 63(1):11-30.
2. Androutsellis-Theotokis A, Leker RR, Soldner F, Hoeppner DJ, Ravin R, Poser SW, et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature. 2006, 442(7104):823-6.
3. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004, 6(6):R605-15.
4. Liu N, Zhang J, Ji C. The emerging roles of Notch signaling in leukemia and stem cells. Biomarker Res. 2013, 1(1):23.
5. Zou J, Li P, Lu F, Liu N, Dai J, Ye J, et al. Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol. 2013;6:3.
6. Aster JC, Blacklow SC. Targeting the Notch pathway: twists and turns on the road to rational therapeutics. J Clin Oncol. 2012, 30(19):2418-20.
7. Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene. 2003, 22(42):6598-608.
8. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood. 2006, 107(6):2223-33.
9. Allen TD, Rodriguez EM, Jones KD, Bishop JM. Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. Cancer Res. 2011, 71(18):6010-8.
10. Baumgart A, Seidl S, Vlachou P, Michel L, Mitova N, Schatz N, et al. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res. 2010, 70(13):5368-78.
11. Chen Y, De Marco MA, Graziani I, Gazdar AF, Strack PR, Miele L, et al. Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res. 2007, 67(17):7954-9.
12. Eliasz S, Liang S, Chen Y, De Marco MA, Machek O, Skucha S, et al. Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene. 2010, 29(17):2488-98.
13. Westhoff B, Colaluca IN, D'Ario G, Donzelli M, Tosoni D, Volorio S, et al. Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci U S A. 2009, 106(52):22293-8.
14. Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacol Ther. 2013, 139(2):95-110.
15. Takebe N, Nguyen D, Yang SX. Targeting Notch signaling pathway in cancer: Clinical development advances and challenges. Pharmacol Ther. 2014, 14(2):140-9.
16. Rand MD, Grimm LM, Artavanis-Tsakonas S, Patriub V, Blacklow SC, Sklar J, et al. Calcium depletion dissociates and activates heterodimeric notch receptors. Mol Cell Biol. 2000, 20(5):1825-35.
17. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999, 398(6727):518-22.
18. De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010, 6(2):99-107.
19. Deangelo DJ, Stone RM, Silverman LB, Stock W, Attar EC, Fearen I, et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol (ASCO Annual Meeting Proceedings). 2006;24:Abst. 6585.
20. Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, et al. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral gamma-secretase inhibitor PF-03084014. Clin Cancer Res. 2014. [Epub ahead of print]
21. Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, et al. Gauging NOTCH1 activation in cancer using immunohistochemistry. PLoS One. 2013, 8(6):e67306.
22. Timmerman LA, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares JM, Diez J, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004, 18(1):99-115.
23. Wang Z, Li Y, Kong D, Sarkar FH. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets. 2010, 11(6):745-51.
24. Kim A, Kim EY, Cho EN, Kim HJ, Kim SK, Chang J, et al. Notch1 destabilizes the adherens junction complex through upregulation of the Snail family of E-cadherin repressors in non-small cell lung cancer. Oncol Rep. 2013, 30(3):1423-9.
25. Li Y, Burns JA, Cheney CA, Zhang N, Vitelli S, Wang F, et al. Distinct expression profiles of Notch-1 protein in human solid tumors: Implications for development of targeted therapeutic monoclonal antibodies. Biologics. 2010;4:163-71.
26. Huang J, Song H, Liu B, Yu B, Wang R, Chen L. Expression of Notch-1 and its clinical significance in different histological subtypes of human lung adenocarcinoma. J Exp Clin Cancer Res. 2013;32:84.
27. Galluzzo P, Bocchetta M. Notch signaling in lung cancer. Expert Rev Anticancer Ther. 2011, 11(4):533-40.
28. Nguyen D, Rubinstein L, Sherman ME, Tomaszewski JE, Takebe N, Ivy P, et al. Differential expression of Notch1 in lung, ovarian and breast cancers. Cancer Res. 2014;74(19 Suppl):Abstract nr 3838.
29. Khan N, Golzar J, Smith NL, Movahed A. Intracardiac extension of a large cell undifferentiated carcinoma of lung. Heart. 2005, 91(4):512.
30. Silva EG, Tornos C, Bailey MA, Morris M. Undifferentiated carcinoma of the ovary. Arch Pathol Lab Med. 1991, 115(4):377-81.
31. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999, 104(3):263-9.
32. Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature. 1998, 393(6683):382-6.
33. Yang SX, Kummar S, Steinberg SM, Murgo AJ, Gutierrez M, Rubinstein L, et al. Immunohistochemical detection of poly (ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Ther. 2009, 8(21):2004-9.
34. Yang SX, Costantino JP, Kim C, Mamounas EP, Nguyen D, Jeong JH, et al. Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. J Clin Oncol. 2010, 28(18):2974-81.